Avanos Medical Croissance future

Future contrôle des critères 0/6

Avanos Medical devrait augmenter son chiffre d'affaires de 4.6% par an.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.0%
Taux de croissance des recettes	4.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	31 Oct 2024

Mises à jour récentes de la croissance future

Recent updates

Some Avanos Medical, Inc. (NYSE:AVNS) Analysts Just Made A Major Cut To Next Year's Estimates

Aug 14

When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?

Aug 13

Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy

Jul 16

We Think Avanos Medical (NYSE:AVNS) Can Manage Its Debt With Ease

Jun 05

Avanos Medical, Inc. (NYSE:AVNS) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing

May 18

Avanos Medical (NYSE:AVNS) Is Looking To Continue Growing Its Returns On Capital

May 07

Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?

Mar 02

Avanos Medical Q4 2022 Earnings Preview

Feb 20

Avanos Medical, Inc. (NYSE:AVNS) Shares Could Be 30% Below Their Intrinsic Value Estimate

Feb 10

Why Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching

Jan 13

Avanos Medical reports Q3 mixed earnings; reaffirms FY22 guidance

Nov 02

Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate

Sep 12

Avanos Medical Q2 2022 Earnings Preview

Aug 08

When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?

May 28

Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?

May 03

Is There An Opportunity With Avanos Medical, Inc.'s (NYSE:AVNS) 41% Undervaluation?

Feb 10

Should You Think About Buying Avanos Medical, Inc. (NYSE:AVNS) Now?

Dec 21

An Intrinsic Calculation For Avanos Medical, Inc. (NYSE:AVNS) Suggests It's 33% Undervalued

Nov 04

Prévisions de croissance des bénéfices et des revenus

NYSE:AVNS - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	756	N/A	N/A	N/A	1
12/31/2025	713	N/A	N/A	N/A	3
12/31/2024	685	N/A	N/A	N/A	3
9/30/2024	682	22	37	56	N/A
6/30/2024	682	7	42	62	N/A
3/31/2024	680	-2	13	31	N/A
12/31/2023	673	-10	15	32	N/A
9/30/2023	682	-11	37	53	N/A
6/30/2023	683	9	35	53	N/A
3/31/2023	684	18	64	82	N/A
12/31/2022	684	22	72	91	N/A
9/30/2022	696	23	90	109	N/A
6/30/2022	708	-23	86	104	N/A
3/31/2022	723	10	72	92	N/A
12/31/2021	587	-31	66	87	N/A
9/30/2021	736	-52	15	36	N/A
6/30/2021	738	2	-5	14	N/A
3/31/2021	715	-38	-21	N/A	N/A
12/31/2020	715	-29	-23	-2	N/A
9/30/2020	720	14	-30	-6	N/A
6/30/2020	705	-17	-51	-24	N/A
3/31/2020	714	-22	-100	-57	N/A
12/31/2019	698	-46	-125	-74	N/A
9/30/2019	678	-42	-139	-79	N/A
6/30/2019	671	-27	-194	-130	N/A
3/31/2019	660	-17	-247	-195	N/A
12/31/2018	652	-8	-195	-146	N/A
9/30/2018	649	-1	-118	-74	N/A
6/30/2018	634	-16	N/A	17	N/A
3/31/2018	622	-28	N/A	134	N/A
12/31/2017	612	-32	N/A	144	N/A
9/30/2017	-171	-150	N/A	125	N/A
6/30/2017	76	-130	N/A	152	N/A
3/31/2017	327	-112	N/A	183	N/A
12/31/2016	566	-83	N/A	189	N/A
9/30/2016	1,584	44	N/A	167	N/A
6/30/2016	1,576	-435	N/A	136	N/A
3/31/2016	1,565	-434	N/A	100	N/A
12/31/2015	509	-101	N/A	98	N/A
9/30/2015	1,612	-443	N/A	115	N/A
6/30/2015	1,631	20	N/A	120	N/A
3/31/2015	1,656	7	N/A	162	N/A
12/31/2014	1,672	27	N/A	148	N/A
9/30/2014	1,664	69	N/A	184	N/A
6/30/2014	1,675	125	N/A	222	N/A
3/31/2014	1,677	168	N/A	210	N/A
12/31/2013	1,678	155	N/A	224	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de AVNS est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de AVNS devraient croître plus rapidement que le marché US

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de AVNS devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de AVNS ( 4.6% par an) devrait croître plus lentement que le marché de US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de AVNS ( 4.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de AVNS devrait être élevé dans 3 ans

Avanos Medical Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.5% to US$25.50

Avanos Medical, Inc. Provides Earnings Guidance for the Full Year 2024

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2024

Avanos Medical, Inc. Provides Earnings Guidance for 2024

Price target decreased by 8.9% to US$25.50

Avanos Medical, Inc. Provides Financial Guidance for the Year 2023

Recent updates

Avanos Medical, Inc. Launches New CORGRIP SR

Third quarter 2024 earnings released: EPS: US$0.13 (vs US$0.19 loss in 3Q 2023)

Avanos Medical, Inc. Announces Chief Executive Officer Changes

Avanos Medical, Inc.'s (NYSE:AVNS) Price Is Right But Growth Is Lacking

Avanos Medical, Inc. to Report Q3, 2024 Results on Oct 30, 2024

There May Be Some Bright Spots In Avanos Medical's (NYSE:AVNS) Earnings

Price target increased by 8.5% to US$25.50

Second quarter 2024 earnings released: EPS: US$0.094 (vs US$0.092 loss in 2Q 2023)

Avanos Medical, Inc. Provides Earnings Guidance for the Full Year 2024

Avanos Medical, Inc. Appoints Indrani Franchini to its Board of Directors

Avanos Medical, Inc. Appoints Sigfrido (Sig) Delgado as Senior Vice President, Integrated Supply Chain

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.17 loss in 1Q 2023)

Avanos Medical, Inc. to Report Q1, 2024 Results on May 02, 2024

Lacklustre Performance Is Driving Avanos Medical, Inc.'s (NYSE:AVNS) Low P/S

CEO & Director exercised options and sold US$302k worth of stock

Senior VP recently sold US$153k worth of stock

Avanos Medical, Inc., Annual General Meeting, Apr 25, 2024

Avanos Medical, Inc. Announces Voluntary Recall of Mic Gastric - Jejunal Feeding Tube Kits

Avanos Medical, Inc. Provides Earnings Guidance for 2024

Full year 2023 earnings released: US$0.21 loss per share (vs US$1.08 profit in FY 2022)

Avanos Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Is Avanos Medical (NYSE:AVNS) A Risky Investment?

Price target decreased by 8.9% to US$25.50

Investor sentiment improves as stock rises 15%

Avanos Medical, Inc. Provides Financial Guidance for the Year 2023

Price target decreased by 8.6% to US$26.50

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.34 profit in 3Q 2022)

Avanos Medical, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Consensus revenue estimates fall by 11%

Some Avanos Medical, Inc. (NYSE:AVNS) Analysts Just Made A Major Cut To Next Year's Estimates

When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?

New minor risk - Earnings quality

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2023

Avanos Medical, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy

Avanos Medical, Inc.(NYSE:AVNS) dropped from Russell 2000 Dynamic Index

Avanos Medical, Inc. (NYSE:AVNS) entered into a definitive agreement to acquire Diros Technology Inc.

SunMed, LLC entered into a Purchase Agreement to acquire Respiratory Health Business from Avanos Medical, Inc. (NYSE:AVNS) for $110 million.

We Think Avanos Medical (NYSE:AVNS) Can Manage Its Debt With Ease

Avanos Medical, Inc. (NYSE:AVNS) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing

Investor sentiment deteriorates as stock falls 21%

Avanos Medical (NYSE:AVNS) Is Looking To Continue Growing Its Returns On Capital

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Avanos Medical Q4 2022 Earnings Preview

Avanos Medical, Inc. Announces Resignation of Arjun R. Sarker as Senior Vice President, Effective May 10, 2023

Avanos Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Avanos Medical, Inc. (NYSE:AVNS) Shares Could Be 30% Below Their Intrinsic Value Estimate

Why Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching

Avanos Medical, Inc. Announces Executive Changes

Insufficient new directors

Avanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain & Procurement

Investor sentiment improved over the past week

Price target decreased to US$27.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avanos Medical, Inc. Affirms Revenue Guidance for the Full-Year 2022

Avanos Medical reports Q3 mixed earnings; reaffirms FY22 guidance

Avanos Medical, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Avanos Medical, Inc. Announces Resignation of Maria Sainz, Member of the Board of Directors, Effective January 1, 2023

Price target decreased to US$32.33

Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Avanos Medical, Inc. Provides Earnings Outlook for the Full Year 2022

Avanos Medical Q2 2022 Earnings Preview

Avanos Medical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$35.00